Jennifer Kim
Stock Analyst at Cantor Fitzgerald
(3.52)
# 856
Out of 5,140 analysts
35
Total ratings
55.88%
Success rate
30.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jennifer Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLTE Belite Bio | Reiterates: Overweight | n/a | $180.95 | - | 5 | May 15, 2025 | |
| PGEN Precigen | Reiterates: Overweight | n/a | $4.38 | - | 4 | May 15, 2025 | |
| INSM Insmed | Reiterates: Overweight | n/a | $164.91 | - | 8 | Feb 20, 2025 | |
| FBIO Fortress Biotech | Reiterates: Overweight | n/a | $3.36 | - | 4 | Jun 20, 2024 | |
| EYPT EyePoint | Reiterates: Overweight | n/a | $15.33 | - | 6 | Jun 20, 2024 | |
| OCGN Ocugen | Maintains: Overweight | $2.5 → $2 | $1.60 | +25.00% | 2 | Aug 31, 2023 | |
| LPCN Lipocine | Reiterates: Overweight | $33 | $9.80 | +236.73% | 2 | Jul 27, 2023 | |
| PRQR ProQR Therapeutics | Maintains: Overweight | $5 → $4.5 | $1.44 | +212.50% | 2 | May 17, 2023 | |
| AYTU Aytu BioPharma | Maintains: Overweight | $220 → $100 | $2.30 | +4,247.83% | 2 | May 17, 2022 |
Belite Bio
May 15, 2025
Reiterates: Overweight
Price Target: n/a
Current: $180.95
Upside: -
Precigen
May 15, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.38
Upside: -
Insmed
Feb 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $164.91
Upside: -
Fortress Biotech
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.36
Upside: -
EyePoint
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.33
Upside: -
Ocugen
Aug 31, 2023
Maintains: Overweight
Price Target: $2.5 → $2
Current: $1.60
Upside: +25.00%
Lipocine
Jul 27, 2023
Reiterates: Overweight
Price Target: $33
Current: $9.80
Upside: +236.73%
ProQR Therapeutics
May 17, 2023
Maintains: Overweight
Price Target: $5 → $4.5
Current: $1.44
Upside: +212.50%
Aytu BioPharma
May 17, 2022
Maintains: Overweight
Price Target: $220 → $100
Current: $2.30
Upside: +4,247.83%